Citi analyst Geoff Meacham downgraded Avidity Biosciences (RNA) to Neutral from Buy with an unchanged price target of $72 after the announcement of the proposed acquisition by Novartis (NVS).
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA: